PL2231667T3 - Inhibitory beta-laktamazy - Google Patents

Inhibitory beta-laktamazy

Info

Publication number
PL2231667T3
PL2231667T3 PL09701487T PL09701487T PL2231667T3 PL 2231667 T3 PL2231667 T3 PL 2231667T3 PL 09701487 T PL09701487 T PL 09701487T PL 09701487 T PL09701487 T PL 09701487T PL 2231667 T3 PL2231667 T3 PL 2231667T3
Authority
PL
Poland
Prior art keywords
beta
lactamase inhibitors
lactamase
inhibitors
Prior art date
Application number
PL09701487T
Other languages
English (en)
Inventor
Timothy A Blizzard
Helen Chen
Candido Gude
Jeffrey D Hermes
Jason E Imbriglio
Seongkon Kim
Jane Y Wu
Sookhee Ha
Christopher J Mortko
Ian Mangion
Nelo Rivera
Rebecca T Ruck
Michael Shevlin
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of PL2231667T3 publication Critical patent/PL2231667T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
PL09701487T 2008-01-18 2009-01-15 Inhibitory beta-laktamazy PL2231667T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1153308P 2008-01-18 2008-01-18
EP09701487.2A EP2231667B1 (en) 2008-01-18 2009-01-15 Beta-lactamase inhibitors
PCT/US2009/031047 WO2009091856A2 (en) 2008-01-18 2009-01-15 Beta-lactamase inhibitors

Publications (1)

Publication Number Publication Date
PL2231667T3 true PL2231667T3 (pl) 2014-01-31

Family

ID=40642204

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13180969T PL2666774T3 (pl) 2008-01-18 2009-01-15 Inhibitory beta-laktamazy
PL09701487T PL2231667T3 (pl) 2008-01-18 2009-01-15 Inhibitory beta-laktamazy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL13180969T PL2666774T3 (pl) 2008-01-18 2009-01-15 Inhibitory beta-laktamazy

Country Status (38)

Country Link
US (2) US8487093B2 (pl)
EP (2) EP2666774B1 (pl)
JP (3) JP5038509B2 (pl)
KR (2) KR101648728B1 (pl)
CN (2) CN101918407B (pl)
AU (1) AU2009206119C1 (pl)
BR (1) BRPI0906871B1 (pl)
CA (1) CA2712783C (pl)
CO (1) CO6331438A2 (pl)
CR (1) CR11626A (pl)
CY (5) CY1114900T1 (pl)
DK (2) DK2231667T3 (pl)
DO (1) DOP2010000218A (pl)
EC (2) ECSP10010345A (pl)
ES (2) ES2433744T3 (pl)
FR (3) FR20C1030I2 (pl)
HN (1) HN2010001395A (pl)
HR (2) HRP20131123T1 (pl)
HU (2) HUS000513I2 (pl)
IL (1) IL206395A (pl)
LT (3) LTC2231667I2 (pl)
LU (1) LUC00165I2 (pl)
MA (1) MA32025B1 (pl)
ME (1) ME02089B (pl)
MX (1) MX2010007823A (pl)
MY (1) MY162532A (pl)
NI (1) NI201000115A (pl)
NL (2) NL301051I2 (pl)
NO (3) NO2020022I1 (pl)
NZ (1) NZ586861A (pl)
PL (2) PL2666774T3 (pl)
PT (2) PT2231667E (pl)
RS (2) RS53862B1 (pl)
RU (1) RU2445314C9 (pl)
SI (2) SI2231667T1 (pl)
UA (1) UA101966C2 (pl)
WO (1) WO2009091856A2 (pl)
ZA (1) ZA201005333B (pl)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2231667T1 (sl) * 2008-01-18 2013-12-31 Merck Sharp & Dohme Corp. Beta laktamazni inhibitorji
BR112013003045B1 (pt) 2010-08-10 2021-08-31 Rempex Pharmaceuticals, Inc. Composto e respectivo uso, composição farmacêutica, recipiente estéril e método para preparar composição farmacêutica para administração
US8772490B2 (en) * 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
CN104892490B (zh) * 2010-12-22 2017-07-21 明治制果药业株式会社 用于制备光学活性二氮杂环辛烷衍生物的中间体化合物的化合物
WO2012172368A1 (en) * 2011-06-17 2012-12-20 Astrazeneca Ab Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
KR101512738B1 (ko) * 2011-08-27 2015-04-17 욱크하르트 리미티드 1,6-디아자-비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도
JP5677634B2 (ja) 2011-08-30 2015-02-25 ウォックハート リミテッド １，６−ジアザビシクロ［３，２，１］オクタン−７−オン誘導体および細菌感染の処置におけるそれらの使用
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
AU2013207510A1 (en) 2012-01-06 2014-07-31 The Regents Of The University Of California Compositions, methods of use, and methods of treatment
US8969570B2 (en) * 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
SG11201406120SA (en) * 2012-03-30 2014-10-30 Cubist Pharm Inc ISOXAZOLE β-LACTAMASE INHIBITORS
MX2014011827A (es) * 2012-03-30 2015-02-20 Cubist Pharm Inc Inhibidores de 1,3,4 - oxadiazol y 1,3,4 - tiadiazol b-lactamasa.
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
WO2013169725A2 (en) 2012-05-08 2013-11-14 Codexis, Inc. Biocatalysts and methods for hydroxylation of chemical compounds
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
UA117734C2 (uk) 2012-05-30 2018-09-25 Мейдзі Сейка Фарма Ко., Лтд. НОВИЙ ІНГІБІТОР β-ЛАКТАМАЗИ І СПОСІБ ЙОГО ОДЕРЖАННЯ
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
BR112015003592B1 (pt) * 2012-08-25 2020-04-14 Wockhardt Ltd derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
US20150315145A1 (en) * 2012-11-01 2015-11-05 Kaneka Corporation Process for producing optically active bicyclic urea compound
KR102147420B1 (ko) * 2012-12-07 2020-08-25 베나토알엑스 파마슈티컬스, 인크. 베타-락타마제 억제제
UA111925C2 (uk) * 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
MX2015008627A (es) 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2894891A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2014110442A1 (en) 2013-01-10 2014-07-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105143224A (zh) * 2013-03-08 2015-12-09 沃克哈特有限公司 一种制备(2s,5r)-硫酸单-{[(4-氨基哌啶-4-基)羰基]-7-氧代-1,6-二氮杂-双环[3.2.1]-辛-6-基}酯的方法
AU2013380573B2 (en) * 2013-03-08 2016-07-07 Wockhardt Limited A process for sodium salt of (2S, 5R)-2-carboxamido-7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane
CN105143225A (zh) 2013-03-08 2015-12-09 沃克哈特有限公司 一种制备(2s,5r)-7-氧代-6-磺酰氧基-2-[((3r)-哌啶-3-羰基)-肼基羰基]-1,6-二氮杂-双环[3.2.1]辛烷的方法
WO2014135931A1 (en) * 2013-03-08 2014-09-12 Wockhardt Limited A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane
KR101774132B1 (ko) 2013-03-08 2017-09-01 욱크하르트 리미티드 (2s, 5r)-7-옥소-6-술포옥시-2-[((3r)-피페리딘-3-카보닐)-히드라지노 카보닐]-1,6-디아자-비사이클로[3.2.1]-옥탄의 제조 방법
US9624222B2 (en) * 2013-03-08 2017-04-18 Wockhardt Limited Process for preparation of (2S, 5R)-7-oxo-6-sulphooxy-2-[((3R)-pyrrolidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octance
US9120795B2 (en) 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
AU2014278556B2 (en) * 2013-06-10 2018-07-19 Merck Sharp & Dohme Llc Preparation of tert-butyl 4-((1R,2S,5R)-6- (benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2- carboxamido)piperidine-1-carboxylate
MY176278A (en) 2013-09-24 2020-07-27 Meiji Seika Pharma Co Ltd Process for producing diazabicyclooctane derivative and intermediate thereof
WO2015051101A1 (en) * 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
NZ757221A (en) 2013-10-08 2021-12-24 Meiji Seika Pharma Co Ltd Crystalline forms of diazabicyclooctane derivative and production process thereof
WO2015079329A2 (en) * 2013-11-26 2015-06-04 Wockhardt Limited A process for preparation of (2s, 5r)-7-oxo-n-[(2s)-pyrrolidin-2-yl-methyloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
ES2719136T3 (es) 2014-03-24 2019-07-08 Novartis Ag Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas
WO2015150891A1 (en) * 2014-03-29 2015-10-08 Wockhardt Limited A process for preparation of trans-sulfuric acid mono-[2-(5-azetidin-3-ylmethyl-[1,3,4]oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo [3.2.1]oct-6-yl]ester
WO2015150890A1 (en) * 2014-03-29 2015-10-08 Wockhardt Limited A process for preparation of trans-sulfuric acid mono-{2-(5-(3-amino-propyl)-[1,3,4]oxadiazol-2-yl]-7-oxo-1,6-diazabicyclo [3.2.1] oct-6-yl}ester
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
RS59488B1 (sr) 2014-05-05 2019-12-31 Rempex Pharmaceuticals Inc Sinteza boronatnih soli i njihove upotrebe
KR20170007448A (ko) 2014-05-19 2017-01-18 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
KR102396753B1 (ko) 2014-06-11 2022-05-12 베나토알엑스 파마슈티컬스, 인크. 베타-락타마제 억제제
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP3164406B1 (en) 2014-07-01 2024-12-25 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
SI3221313T1 (sl) 2014-11-17 2019-04-30 Entasis Therapeutics Limited Kombinacijska terapija za zdravljenje okužb z rezistentnimi bakterijami
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2016089718A1 (en) 2014-12-02 2016-06-09 Merck Sharp & Dohme Corp. Process for the preparation of tert-butyl 4-((2s,5r)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate and analogs thereof
BR112017010445B8 (pt) 2014-12-05 2024-02-27 Meiji Seika Pharma Co Ltd Processo de produção de cristais de derivado de diazabiciclo-octano e preparação liofilizada estável
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10570131B2 (en) 2015-03-31 2020-02-25 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
MX2017014080A (es) * 2015-05-07 2018-07-06 Mutabilis Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
EP3347008B1 (en) 2015-09-11 2022-03-09 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP3281942A4 (en) * 2015-09-16 2018-08-15 Xuanzhu Pharma Co., Ltd. B-lactamase inhibitor and application thereof
CN108137567A (zh) 2015-10-02 2018-06-08 乐高化学生物科学股份有限公司 用于抑制β-内酰胺酶的组合物和方法
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP3386982A1 (en) * 2015-12-11 2018-10-17 The Wockhardt Limited 7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide containing compounds and their use in treating bacterial infections
US10472345B2 (en) 2016-02-04 2019-11-12 Merck Sharp & Dohme Corp. Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents
CN108778270B (zh) * 2016-03-31 2021-07-30 吉林四环制药有限公司 一种抗菌组合物及其用途
WO2017213758A1 (en) 2016-06-09 2017-12-14 Codexis, Inc. Biocatalysts and methods for hydroxylation of chemical compounds
US10294249B2 (en) 2016-06-30 2019-05-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
SMT202200397T1 (it) * 2016-09-16 2022-11-18 Entasis Therapeutics Ltd Composti inibitori di beta-lattamasi
EP3515915B1 (en) * 2016-09-19 2021-08-04 Merck Sharp & Dohme Corp. Process for preparing beta-lactamase inhibitor hydroxylurea intermediates
JOP20190061A1 (ar) * 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN108078982B (zh) * 2016-11-21 2020-02-07 天津大学 脯氨酸衍生物在制备β-内酰胺酶抑制剂中的用途
PL3592362T3 (pl) 2017-03-06 2025-06-23 VenatoRx Pharmaceuticals, Inc. Postacie stałe i kompozycje skojarzone zawierające inhibitor beta-laktamaz i ich zastosowania
CN108619141B (zh) * 2017-03-16 2021-09-10 山东轩竹医药科技有限公司 一种抗菌组合物及其用途
CN110709081B (zh) 2017-05-08 2023-09-22 恩塔西斯治疗公司 用于治疗细菌感染的化合物及方法
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
SG11202000217QA (en) 2017-07-21 2020-02-27 Antabio Sas Chemical compounds
CN109568323B (zh) * 2017-09-29 2022-09-30 吉林四环制药有限公司 抗菌组合物及其用途
US11286270B2 (en) 2017-10-11 2022-03-29 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
EP3719020B1 (en) 2017-12-01 2022-09-21 Qilu Pharmaceutical Co., Ltd. Crystal form of beta-lactamase inhibitor and preparation method therefor
CN109956941B (zh) * 2017-12-25 2020-08-04 新发药业有限公司 一种阿维巴坦的简便制备方法
EP3744722A4 (en) 2018-01-25 2021-11-03 Suzhou Sinovent Pharmaceuticals Co., Ltd. Ss-LACTAMASE INHIBITOR AND ITS USE
EP3781576B1 (en) 2018-04-20 2024-06-12 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3670512A1 (en) * 2018-12-18 2020-06-24 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3833665B1 (en) * 2018-08-09 2023-07-19 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11897844B2 (en) * 2018-09-21 2024-02-13 Api Corporation Method for producing amino acid derivatives
WO2020072442A1 (en) * 2018-10-01 2020-04-09 Arixa Pharmaceuticals, Inc. Derivatives of relebactam and uses thereof
CN111072660B (zh) * 2018-10-22 2021-05-18 新发药业有限公司 一种瑞来巴坦的简便制备方法
SG11202108905UA (en) 2019-03-12 2021-09-29 Arixa Pharmaceuticals Inc Crystalline form of an avibactam derivative
CN114206851B (zh) 2019-04-26 2025-02-11 默沙东有限责任公司 可用于制备(2s,5r)-7-氧代-n-哌啶-4-基-6-(硫酸基)-1,6-二氮杂双环[3.2.1]辛烷-2-甲酰胺的中间体的制备方法
JP7647110B2 (ja) * 2020-01-22 2025-03-18 日油株式会社 ポリエーテルエステル化合物
EP4146650A4 (en) 2020-09-01 2024-01-17 Ningxia Academy of Agriculture and Forestry Sciences BETA-LACTAMASE INHIBITORS AND THEIR PRODUCTION
WO2022047790A1 (en) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
CN111943950B (zh) * 2020-09-10 2022-03-29 山东安信制药有限公司 一种瑞来巴坦的制备方法
EP4146651A4 (en) 2021-05-07 2024-06-05 Ningxia Academy of Agriculture and Forestry Sciences SULFONYLAMIDINE SUBSTITUTED COMPOUNDS AND THEIR USE AS BETA-LACTAMASE INHIBITORS
US11814385B2 (en) * 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation
US20250302846A1 (en) * 2022-05-11 2025-10-02 The Regents Of The University Of Colorado A Body Corporate Antibiotic composition and methods of use thereof
CN117384169B (zh) * 2022-07-05 2025-10-17 福安药业集团重庆三禾兴医药科技有限公司 一类噻唑胺-二氮杂双环辛酮缀合衍生物及其用途
GB202306833D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
GB202306826D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4616038A (en) 1978-07-24 1986-10-07 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
US4880793A (en) 1978-07-24 1989-11-14 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
US5071843A (en) 1978-07-24 1991-12-10 Merck & Co., Inc. Combination of 2-substituted carbapenems with dipeptidase inhibitors
US4539208A (en) 1980-09-17 1985-09-03 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
ES2090393T3 (es) 1991-04-11 1996-10-16 Hoffmann La Roche Beta-lactamas.
CZ282567B6 (cs) 1993-12-29 1997-08-13 Pfizer Inc. Diazabicyklické sloučeniny a farmaceutické prostředky na jejich bázi
JP3199300B2 (ja) * 1994-05-09 2001-08-13 三共株式会社 １−メチルカルバペネム誘導体
DE69623497T2 (de) 1995-12-21 2003-05-28 Sankyo Co., Ltd. 1-methylcarbapenem-derivate
JP2965922B2 (ja) * 1995-12-21 1999-10-18 三共株式会社 １−メチルカルバペネム誘導体
JP2955276B2 (ja) * 1997-06-19 1999-10-04 三共株式会社 １−メチルカルバペネム誘導体を含有する抗菌剤
JP4490517B2 (ja) * 1998-03-19 2010-06-30 富山化学工業株式会社 ５−デオキシ−５−アルカノイルアミノ−β−Ｄ−アロフラノシルウロン酸誘導体またはその塩、それらを含有する抗真菌剤及びキチン合成酵素阻害剤
JP4226818B2 (ja) 1999-07-06 2009-02-18 メチルジーン・インコーポレーテッド ベータ−ラクタマーゼのスルフォンアミドメチルホスホン酸阻害剤
WO2001010834A2 (en) 1999-08-10 2001-02-15 British Biotech Pharmaceuticals Limited Antibacterial agents
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
JP2002212182A (ja) * 2000-11-16 2002-07-31 Sankyo Co Ltd １−メチルカルバペネム誘導体
ES2273902T3 (es) 2000-11-16 2007-05-16 Sankyo Company, Limited Derivados de 1-metilcarbapenem.
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JP2004043438A (ja) * 2002-05-15 2004-02-12 Sankyo Co Ltd １−メチルカルバペネム誘導体を含有する医薬
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
CN1845897A (zh) * 2003-07-09 2006-10-11 帕拉特克药品公司 取代的四环素化合物
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
JP2008502583A (ja) 2003-10-01 2008-01-31 バイエル・ヘルスケア・アクチェンゲゼルシャフト 抗細菌性アミド大員環
WO2005082050A2 (en) 2004-02-24 2005-09-09 Ssci, Inc. Analysis and screening of solid forms using the atomic pair distribution function
SI1965798T1 (sl) * 2005-12-07 2012-01-31 Basilea Pharmaceutica Ag Uporabni monobaktamski antibiotiki
US20100009957A1 (en) 2006-09-27 2010-01-14 Blizzard Timothy A Novel inhibitors of beta-lactamase
SI2231667T1 (sl) * 2008-01-18 2013-12-31 Merck Sharp & Dohme Corp. Beta laktamazni inhibitorji

Also Published As

Publication number Publication date
CY2020023I1 (el) 2020-11-25
UA101966C2 (en) 2013-05-27
NO2020024I1 (no) 2020-08-10
US20110294777A1 (en) 2011-12-01
FR20C1031I2 (fr) 2022-07-29
FR20C1032I2 (fr) 2022-07-29
NO2020022I1 (no) 2020-08-10
EP2231667A2 (en) 2010-09-29
DK2231667T3 (da) 2013-12-16
NO2020023I1 (no) 2020-08-10
CN102827067B (zh) 2015-09-23
AU2009206119C1 (en) 2016-05-26
CA2712783C (en) 2013-03-19
CY2020024I2 (el) 2020-11-25
CY2020023I2 (el) 2020-11-25
IL206395A (en) 2015-04-30
CN102827067A (zh) 2012-12-19
KR20160099117A (ko) 2016-08-19
LTPA2020517I1 (lt) 2020-07-27
ES2433744T3 (es) 2013-12-12
KR20100130176A (ko) 2010-12-10
JP2011510012A (ja) 2011-03-31
EP2231667B1 (en) 2013-09-04
MX2010007823A (es) 2010-08-10
WO2009091856A2 (en) 2009-07-23
DK2666774T3 (en) 2015-03-23
IL206395A0 (en) 2010-12-30
CY2020025I2 (el) 2020-11-25
ECSP10010568A (es) 2010-11-30
HN2010001395A (es) 2012-11-12
KR101800610B1 (ko) 2017-11-23
KR101648728B1 (ko) 2016-08-17
LTPA2020516I1 (lt) 2020-07-27
AU2009206119B2 (en) 2012-06-07
EP2666774A1 (en) 2013-11-27
LTPA2020518I1 (lt) 2020-07-27
JP2011207900A (ja) 2011-10-20
HUS2000024I1 (hu) 2021-03-29
WO2009091856A3 (en) 2009-12-03
LTC2666774I2 (lt) 2022-01-25
FR20C1030I1 (fr) 2020-02-10
FR20C1032I1 (pl) 2020-02-10
RU2445314C1 (ru) 2012-03-20
CY1116243T1 (el) 2017-03-15
CY2020024I1 (el) 2020-11-25
ME02089B (me) 2014-04-30
HRP20131123T1 (hr) 2013-12-20
MY162532A (en) 2017-06-15
BRPI0906871A2 (pt) 2020-07-28
CN101918407A (zh) 2010-12-15
LUC00165I2 (pl) 2021-08-16
JP2012214475A (ja) 2012-11-08
JP5597164B2 (ja) 2014-10-01
RS53862B1 (sr) 2015-08-31
US8487093B2 (en) 2013-07-16
PL2666774T3 (pl) 2015-06-30
RU2445314C9 (ru) 2013-04-10
US20130274475A1 (en) 2013-10-17
NL301051I2 (nl) 2020-09-03
NI201000115A (es) 2011-07-08
HK1186180A1 (en) 2014-03-07
CA2712783A1 (en) 2009-07-23
HUS000504I2 (hu) 2021-03-29
CY1114900T1 (el) 2016-12-14
FR20C1031I1 (pl) 2020-02-10
MA32025B1 (fr) 2011-01-03
NL301050I2 (nl) 2020-09-03
EP2666774B1 (en) 2015-01-07
PT2231667E (pt) 2013-12-13
SI2231667T1 (sl) 2013-12-31
CO6331438A2 (es) 2011-10-20
HUS2000023I1 (hu) 2021-03-29
CY2020025I1 (el) 2020-11-25
HUS000513I2 (hu) 2021-03-29
DOP2010000218A (es) 2010-08-31
PT2666774E (pt) 2015-04-13
ECSP10010345A (es) 2010-08-31
SI2666774T1 (sl) 2015-04-30
JP5038509B2 (ja) 2012-10-03
LTC2231667I2 (lt) 2021-07-26
HK1143809A1 (en) 2011-01-14
HRP20150269T1 (hr) 2015-04-24
RS53052B (sr) 2014-04-30
CN101918407B (zh) 2014-02-26
FR20C1030I2 (fr) 2021-08-27
ZA201005333B (en) 2011-04-28
CR11626A (es) 2010-09-13
NZ586861A (en) 2011-12-22
ES2533826T3 (es) 2015-04-15
JP5422020B2 (ja) 2014-02-19
AU2009206119A1 (en) 2009-07-23
BRPI0906871B1 (pt) 2021-09-28

Similar Documents

Publication Publication Date Title
HUS2000023I1 (hu) Beta-laktamáz inhibitorok
ZA201002467B (en) Beta-lactamase inhibitors
ZA201100467B (en) Cmet inhibitors
IL211018A0 (en) Novel inhibitors
EP2209474A4 (en) BROAD SPECTRUM BETA-LACTAMASE INHIBITORS
ZA201102837B (en) Phosphodiestarase inhibitors
ZA201102179B (en) Protease inhibitors
GB0817425D0 (en) Protease inhibitors
GB0714941D0 (en) Inhibitors
GB201019387D0 (en) Inhibitors
GB0816125D0 (en) Novel inhibitors
GB0713152D0 (en) Phosphodlesterase inhibitors
HK1160453A (en) Phosphodiestarase inhibitors
GB0707499D0 (en) Novel inhibitors
GB0707497D0 (en) Novel inhibitors
GB0707498D0 (en) Novel inhibitors
GB0707632D0 (en) Novel inhibitors
GB0707493D0 (en) Novel inhibitors
GB0707488D0 (en) Novel inhibitors
GB0704589D0 (en) Novel inhibitors
GB0707495D0 (en) Novel inhibitors
GB0807056D0 (en) Enzyme inhibitors
GB0812443D0 (en) Enzyme inhibitors